CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 35 enrolled
Drug / intervention
Isovue 370 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02171247
NCT02171247Phase 3Completed
CompareCT.gov

Comparison of the Use of High Iodine Concentration Contrast Material (Isovue 370) vs. Standard Protocol in Coronary Computed Tomographic Angiography (CTA)

Duke University·interventional·Posted Jun 24, 2014·Updated Aug 15, 2014

In Brief

A Phase 3 clinical trial evaluating Isovue 370 and Visipaque 320 for Coronary Computed Tomographic Angiography. Completed, enrolled 35 participants.

Detailed Summary

Computed Tomography Angiogram (CTA) scans are performed routinely to look at the vessels in the body as an alternative to directly injecting contrast into the vessels and taking pictures. Different types of intravenous (into the vein, IV) contrast are available to fill the vessels and make them easier to see. The purpose of the study is to determine the best type of contrast for this scan.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Computed Tomographic Angiography
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 24, 2014
Enrollment StartApr 1, 2008
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 12.0 years ago

Interventions

Isovue 370drug

Isovue 370 is a contrast agent with increased iodine concentration.

Visipaque 320drug

Visipaque 320 is standard protocol.